Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...
The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.
Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...
As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and ...
GlobalData on MSN19h
Spirovant Sciences doses first subject in cystic fibrosis gene therapy trialSpirovant Sciences has announced the commencement of its SAAVe Phase I/II study, with the first patient receiving a dose of ...
Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen. Thank you for standing by.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback